Valuation Regeneron Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
750.57 ^USD	+0.61%		+0.23%	-2.76%

Apr. 15	Sanofi and Regeneron?s Dupixent approval in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria	CI
Apr. 15	Sanofi and Regeneron?S Dupixent Approves in the Eu as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Capitalization ¹	66,029	77,057	93,403	76,639	79,193	77,023	-	-
Change	-	16.7%	21.21%	-17.95%	3.33%	-2.74%	-	-
Enterprise Value (EV) ¹	56,196	77,057	84,542	70,331	73,294	68,951	66,106	62,699
Change	-	37.12%	9.71%	-16.81%	4.21%	-5.93%	-4.13%	-5.15%
P/E ratio	8.77x	18.9x	25.3x	18.6x	18.6x	19.3x	15.8x	13.6x
PBR	3.56x	3.41x	3.64x	2.62x	2.58x	2.24x	1.99x	1.75x
PEG	-	-0.4x	-2.8x	1.8x	2.27x	-3.16x	0.7x	0.8x
Capitalization / Revenue	4.11x	6.33x	7.12x	5.4x	5.52x	4.9x	4.44x	4.11x
EV / Revenue	3.5x	6.33x	6.45x	4.95x	5.11x	4.38x	3.81x	3.34x
EV / EBITDA	5.71x	12.7x	15.2x	12.3x	13.5x	13.2x	11x	8.92x
EV / EBIT	6.28x	13.5x	16.5x	13.5x	15x	13.5x	10.5x	8.77x
EV / FCF	8.61x	17.4x	21.8x	19.2x	18x	14.1x	11.7x	9.63x
FCF Yield	11.6%	5.74%	4.58%	5.21%	5.57%	7.12%	8.58%	10.4%
Dividend per Share ²	-	-	-	-	3.52	3.862	4.353	4.869
Rate of return	-	-	-	-	0.46%	0.51%	0.58%	0.65%
EPS ²	71.97	38.22	34.77	38.34	41.48	38.95	47.55	55.22
Distribution rate	-	-	-	-	8.49%	9.91%	9.15%	8.82%
Net sales ¹	16,072	12,173	13,117	14,202	14,343	15,727	17,350	18,751
EBITDA ¹	9,835	6,060	5,547	5,695	5,428	5,231	6,018	7,026
EBIT ¹	8,947	5,719	5,126	5,212	4,884	5,106	6,309	7,153
Net income ¹	8,075	4,338	3,954	4,413	4,505	4,235	5,277	6,026
Net Debt ¹	-9,833	-	-8,862	-6,308	-5,899	-8,072	-10,918	-14,324
Reference price ²	631.52	721.49	878.29	712.33	771.87	750.57	750.57	750.57
Nbr of stocks (in thousands)	104,556	106,802	106,347	107,590	102,599	102,620	-	-
Announcement Date	2/4/22	2/3/23	2/2/24	2/4/25	1/30/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
REGENERON PHARMACEUTICALS, INC.	19.27x	4.38x	13.18x	0.51%	77.02B
UCB	28.81x	5.76x	16.65x	0.55%	59.3B
SAMSUNG BIOLOGICS CO.,LTD.	38.99x	13.14x	24.04x	-.--%	50.73B
CSL LIMITED	35.5x	3.56x	10.3x	2.99%	47.29B
BIOGEN INC.	14.9x	2.82x	8.42x	-.--%	26.03B
MODERNA, INC.	-7.42x	8.35x	-6.15x	-.--%	21.3B
INNOVENT BIOLOGICS, INC.	82.79x	9.56x	95.58x	-.--%	20.28B
INCYTE CORPORATION	15.76x	2.56x	8.07x	-.--%	19.47B
SWEDISH ORPHAN BIOVITRUM AB	24.95x	5.05x	13.75x	-.--%	15.94B
BRIDGEBIO PHARMA, INC.	-39.37x	17.75x	-49.52x	-.--%	14.88B
Average	21.42x	7.29x	13.43x	0.41%	35.22B
Weighted average by Cap.	25.20x	6.68x	15.26x	0.61%